Cocrystal pharma discusses antiviral therapeutics' clinical development and 2024 value catalysts in new ceo video interview on planet microcap

Los angeles, ca / accesswire / march 5, 2024 / planet microcap today published a new video interview with jim martin, co-ceo and cfo, from cocrystal pharma, inc. (nasdaq:cocp), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including sars-cov-2) noroviruses and hepatitis c viruses, according to the company's website (see here: https://www.cocrystalpharma.com/). click the following link to watch the video interview: cocrystal pharma discusses antiviral therapeutics' clinical development and 2024 value catalysts you can follow planet microcap on twitter, linkedin, youtube please review important disclosures on our website at: https://snn.network/terms-of-use about cocrystal pharma, inc. cocrystal pharma, inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including sars-cov-2) noroviruses and hepatitis c viruses.
COCP Ratings Summary
COCP Quant Ranking